Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.

Patients with pancreatic cancer have dismal prognoses, and novel therapies are urgently needed. Mutations of the KRAS oncogene occur frequently in pancreatic cancer and represent an attractive target. Direct targeting of the predominant KRAS pathways have been challenging and research into therapeut...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hua Zhong, Cesar Sanchez, Dirk Spitzer, Stacy Plambeck-Suess, Jesse Gibbs, Williams G Hawkins, David Denardo, Feng Gao, Robert A Pufahl, Albert C Lockhart, Mai Xu, David Linehan, Jason Weber, Andrea Wang-Gillam
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0d201c298dc440a981449a4b27ac0bee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0d201c298dc440a981449a4b27ac0bee
record_format	dspace
spelling	oai:doaj.org-article:0d201c298dc440a981449a4b27ac0bee2021-11-18T08:51:43ZSynergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.1932-620310.1371/journal.pone.0077243https://doaj.org/article/0d201c298dc440a981449a4b27ac0bee2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24130864/?tool=EBIhttps://doaj.org/toc/1932-6203Patients with pancreatic cancer have dismal prognoses, and novel therapies are urgently needed. Mutations of the KRAS oncogene occur frequently in pancreatic cancer and represent an attractive target. Direct targeting of the predominant KRAS pathways have been challenging and research into therapeutic strategies have been now refocused on pathways downstream of KRAS, phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK [MEK]). We hypothesized that concurrent inhibition of the PI3K and MEK pathways would result in synergistic antitumor activity, as it would circumvent the compensatory feedback loop between the two pathways. We investigated the combined effect of the PI3K inhibitor, GDC0941, and the MEK inhibitor, AZD6244, on cell viability, apoptosis and cell signaling in a panel of pancreatic cancer cell lines. An in vivo analysis was conducted on pancreatic cancer xenografts. While BxPC-3 (KRAS wild type) and MIA PaCa-2 (KRAS mutated) cell lines were sensitive to GDC0941 and AZD6244 as single agents, synergistic inhibition of tumor cell growth and induction of apoptosis were observed in both cell lines when the two drugs were combined. Interestingly, phosphorylation of the cap-dependent translational components, 4E-binding protein (p-4E-BP1) and S6 was found to be closely associated with sensitivity to GDC0941 and AZD6244. In BxPC-3 cell xenografts, survival differences were observed between the control and the AZD6244, GDC0941, and combination groups. Our study provides the rationale for concurrent targeting of the PI3K and MEK pathways, regardless of KRAS status, and suggests that phosphorylation of 4E-BP1and S6 can serve as a predictive biomarker for response to treatment.Hua ZhongCesar SanchezDirk SpitzerStacy Plambeck-SuessJesse GibbsWilliams G HawkinsDavid DenardoFeng GaoRobert A PufahlAlbert C LockhartMai XuDavid LinehanJason WeberAndrea Wang-GillamPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 10, p e77243 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hua Zhong Cesar Sanchez Dirk Spitzer Stacy Plambeck-Suess Jesse Gibbs Williams G Hawkins David Denardo Feng Gao Robert A Pufahl Albert C Lockhart Mai Xu David Linehan Jason Weber Andrea Wang-Gillam Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
description	Patients with pancreatic cancer have dismal prognoses, and novel therapies are urgently needed. Mutations of the KRAS oncogene occur frequently in pancreatic cancer and represent an attractive target. Direct targeting of the predominant KRAS pathways have been challenging and research into therapeutic strategies have been now refocused on pathways downstream of KRAS, phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK [MEK]). We hypothesized that concurrent inhibition of the PI3K and MEK pathways would result in synergistic antitumor activity, as it would circumvent the compensatory feedback loop between the two pathways. We investigated the combined effect of the PI3K inhibitor, GDC0941, and the MEK inhibitor, AZD6244, on cell viability, apoptosis and cell signaling in a panel of pancreatic cancer cell lines. An in vivo analysis was conducted on pancreatic cancer xenografts. While BxPC-3 (KRAS wild type) and MIA PaCa-2 (KRAS mutated) cell lines were sensitive to GDC0941 and AZD6244 as single agents, synergistic inhibition of tumor cell growth and induction of apoptosis were observed in both cell lines when the two drugs were combined. Interestingly, phosphorylation of the cap-dependent translational components, 4E-binding protein (p-4E-BP1) and S6 was found to be closely associated with sensitivity to GDC0941 and AZD6244. In BxPC-3 cell xenografts, survival differences were observed between the control and the AZD6244, GDC0941, and combination groups. Our study provides the rationale for concurrent targeting of the PI3K and MEK pathways, regardless of KRAS status, and suggests that phosphorylation of 4E-BP1and S6 can serve as a predictive biomarker for response to treatment.
format	article
author	Hua Zhong Cesar Sanchez Dirk Spitzer Stacy Plambeck-Suess Jesse Gibbs Williams G Hawkins David Denardo Feng Gao Robert A Pufahl Albert C Lockhart Mai Xu David Linehan Jason Weber Andrea Wang-Gillam
author_facet	Hua Zhong Cesar Sanchez Dirk Spitzer Stacy Plambeck-Suess Jesse Gibbs Williams G Hawkins David Denardo Feng Gao Robert A Pufahl Albert C Lockhart Mai Xu David Linehan Jason Weber Andrea Wang-Gillam
author_sort	Hua Zhong
title	Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
title_short	Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
title_full	Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
title_fullStr	Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
title_full_unstemmed	Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
title_sort	synergistic effects of concurrent blockade of pi3k and mek pathways in pancreatic cancer preclinical models.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/0d201c298dc440a981449a4b27ac0bee
work_keys_str_mv	AT huazhong synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT cesarsanchez synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT dirkspitzer synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT stacyplambecksuess synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT jessegibbs synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT williamsghawkins synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT daviddenardo synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT fenggao synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT robertapufahl synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT albertclockhart synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT maixu synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT davidlinehan synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT jasonweber synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels AT andreawanggillam synergisticeffectsofconcurrentblockadeofpi3kandmekpathwaysinpancreaticcancerpreclinicalmodels
_version_	1718421185455194112

Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.

Ejemplares similares